Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply

JAMA Oncol. 2023 Mar 1;9(3):436-437. doi: 10.1001/jamaoncol.2022.7361.

Authors

Thierry Conroy¹, Florence Castan², Pascal Hammel³

Affiliations

¹ Department of Medical Oncology, Institut de Cancérologie de Lorraine and APEMAC, équipe MICS, Université de Lorraine, Nancy, France.
² Institut Régional du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
³ Digestive and Medical Oncology department, Hôpital Paul Brousse and University Paris-Saclay, Villejuif, France.

PMID: 36701135
DOI: 10.1001/jamaoncol.2022.7361

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Fluorouracil / therapeutic use
Humans
Leucovorin / therapeutic use
Pancreatic Neoplasms* / drug therapy

Substances

Fluorouracil
Leucovorin